Cellular Biomedicine Group, Inc. (OTCQB: CBMG) today announced the interim results of its Phase I/IIa clinical trial for human adipose-derived mesenchymal precursor cell (haMPC) therapy for Knee Osteoarthritis (KOA), which tests the safety and efficacy of intra-articular injections of autologous (patient's own) haMPCs in order to reduce inflammation and repair damaged joint cartilage. On schedule for completion in Q4 2013, the interim analysis of the trial has preliminarily demonstrated a significant improvement (P<0.05) from the baseline in clinical scores for SF-36, NRS-11, and WOMAC osteoarthritis indices, and no serious adverse events have been reported.
"We are very pleased with the results of the trial thus far and we look forward to the full data readout before the end of the year," said Wei (William) Cao, PhD, BM, President at Cellular Biomedicine Group. "Knee osteoarthritis severely impacts one's quality of life, and surgical treatment is very costly and invasive. This trial's preliminary results have encouraged us to continue with the study to further test the efficacy of this hopeful therapy to reduce pain, repair knee cartilage and improve quality of life of the patients in the next Phase II trial."
Knee Osteoarthritis in China
There are approximately 57 million people in China suffering from knee osteoarthritis. As drug-based methods of management are ineffective, many patients with this disease will degenerate to the point of requiring invasive artificial joint replacement surgery.